Comparative Effectiveness and Cost-Effectiveness of Generic Alendronate, Risendronate, Denosumab and Zolendronic Acid for Secondary Prevention of Fragility Fractures - Perliminay Results
Nov 1, 2015, 00:00
10.1016/j.jval.2015.09.2329
https://www.valueinhealthjournal.com/article/S1098-3015(15)04405-8/fulltext
Title :
Comparative Effectiveness and Cost-Effectiveness of Generic Alendronate, Risendronate, Denosumab and Zolendronic Acid for Secondary Prevention of Fragility Fractures - Perliminay Results
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)04405-8&doi=10.1016/j.jval.2015.09.2329
First page :
A648
Section Title :
Research Podium Presentations - Session 1 and Session 2
Open access? :
No
Section Order :
1736